Tenon Medical Inc. (TNON)

Tenon Medical, trading on the NASDAQ under the symbol TNON, is a pre-commercial medical device company founded to address a large but underserved problem in orthopedic surgery: chronic pain in the sacroiliac joint. The sacroiliac joint, where the sacrum at the base of the spine connects to the pelvis, is a common source of lower back pain in adults. Despite affecting millions of people, treatment options have been limited. Physical therapy helps some; spinal fusion surgery, the historical gold standard, is invasive and has high morbidity. Tenon’s strategy is to occupy the middle ground—a device that stabilizes the joint with minimal tissue disruption and quicker recovery than fusion.

The sacroiliac joint pain problem

The sacroiliac joint carries load and motion in concert with the hip and lumbar spine. Inflammation, degeneration, or misalignment of this joint can cause pain that radiates into the buttock, hip, or lower leg, often severe enough to disable patients. Standard treatment algorithms begin with conservative care: physical therapy, anti-inflammatory drugs, and in some cases steroid injections into the joint space. Many patients improve. Others plateau—their pain persists despite these interventions, leaving them with limited options. The historical surgical choice was lumbar fusion, a procedure that removes intervertebral discs and solidifies portions of the spine. Fusion is durable but carries the downsides of open spinal surgery: long hospital stays, wound complications, long rehabilitation, and the possibility of accelerated degeneration above or below the fused segment.

In recent years, a new category of sacroiliac joint implants emerged. These devices, inserted through minimally invasive surgery, stabilize the joint without fusing the spine. The patient goes home with local anesthesia or short general anesthesia, avoids large incisions, and recovers function in weeks rather than months. As the orthopedic market learned that sacroiliac joint disorders were a distinct diagnosis with distinct treatment—and as orthopedic surgeons refined their surgical technique for implanting these devices—the market began to grow.

Tenon’s implant design

Tenon Medical’s core product is a titanium implant designed to stabilize the sacroiliac joint through a single percutaneous insertion. The implant is robust, engineered to withstand the mechanical forces the joint experiences during load-bearing and motion. The company’s differentiation rests on the elegance of its design: a single implant, inserted through a small opening, that achieves stability without requiring multiple implants or requiring fusion.

The surgical approach is minimally invasive. An orthopedic surgeon or neurosurgeon makes a small incision, uses fluoroscopic imaging to guide the implant to the correct position across the joint, and secures it in place. The procedure can typically be completed in under an hour, often using conscious sedation rather than general anesthesia, and the patient is discharged the same day or the next morning.

Recovery is measured in weeks rather than months. Patients can usually return to light activities within days and resume normal activity within a month or two, depending on their pain response and the surgeon’s protocol. This is dramatically faster than lumbar fusion, which typically requires 6–12 weeks of restricted activity.

The business challenge

The device performs well in clinical settings, but commercial success in medical devices depends on more than clinical efficacy. It depends on reimbursement (whether insurers will pay for the procedure), adoption (whether surgeons will learn and use the device), and manufacturing scale (whether the company can make the device reliably and cost-effectively).

Reimbursement is the critical bottleneck. In the United States, health insurers determine whether they will cover a procedure and at what reimbursement rate. If reimbursement is low, hospitals and surgeons may not view the procedure as worth their time. If reimbursement is not available (because the insurer categorizes the procedure as investigational or not medically necessary), adoption cannot gain traction. Tenon must navigate this landscape with clinical data demonstrating safety and efficacy.

Surgeon adoption requires both clinical conviction and economic incentive. Orthopedic surgeons are busy; learning a new procedure requires time, training, and often attendance at company-sponsored courses. The surgeon must believe the device works and that patients will benefit. The surgeon must also believe the procedure is reimbursed at a rate that makes it worth their time. Early on, a new device company often sponsors procedures or provides educational support to accelerate adoption.

Manufacturing is a third lever. The device is made of titanium and must be produced to precision tolerances. As volumes grow, the company must scale production without sacrificing quality. This typically requires outside manufacturing partners who specialize in medical device fabrication.

The path to profitability

Tenon’s current challenge is to move from promising device to commercial entity. The company has not yet achieved significant revenue; it is focused on completing clinical studies, obtaining regulatory clearance where needed, building relationships with key opinion leaders in orthopedic surgery, and securing insurance coverage. These steps can take years.

The financial path is capital-intensive. The company must fund research, clinical trials, regulatory submissions, and the sales and marketing infrastructure necessary to drive adoption. Historically, medical device startups finance this burn through venture capital, sometimes supplemented by debt or partnerships with larger medical device companies. Tenon has pursued this path, raising capital from investors willing to accept years of losses in exchange for potential future profits if the device achieves meaningful market adoption.

The upside scenario is substantial. If sacroiliac joint implantation becomes the standard of care for patients with treatment-refractory sacroiliac pain, the addressable market could be hundreds of thousands of procedures annually in the United States alone. At typical reimbursement rates and margins, that could support a profitable business. The downside scenario is that adoption remains limited because surgeons prefer fusion or because insurance coverage remains inadequate, leaving the company unable to scale.

Current status and strategy

Tenon Medical remains a pre-commercial company with limited revenue. The company’s strategy is focused on three elements: completing necessary clinical studies and obtaining regulatory clearance for its implant, expanding the surgeon network trained and credentialed to use the device, and working with major insurance providers to establish coverage and reimbursement.

The company’s burn rate and available capital dictate the pace. If the company is burning millions annually and has only years of capital on the balance sheet, the timeline to profitability or break-even is constrained. In this scenario, achieving a transaction—a strategic acquisition by a larger medical device company, a partnership, or a capital raise—becomes likely before or in parallel with independence.

For investors, the key is to track clinical trial progress and regulatory milestones, as these determine whether reimbursement negotiations can succeed and whether surgeon adoption can accelerate. Early adoption rates in key markets and initial payer coverage agreements would be positive signals that the company is on a path to scale.